Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth restriction
Intrauterine growth restriction (IUGR) is a serious pregnancy complication affecting approximately 8% of all pregnancies. The aetiology is believed to be insufficient maternal uteroplacental perfusion which prevents adequate nutrient and oxygen availability for the fetus. There is no treatment that...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
David, Anna L. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
7 |
|---|
| Übergeordnetes Werk: |
Enthalten in: O045 : Bioactive lipids in the human liver in ‘Common NAFLD’ and ‘PNPLA3 NAFLD’ - Luukkonen, P. ELSEVIER, 2015, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:59 ; year:2017 ; pages:44-50 ; extent:7 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.placenta.2017.09.011 |
|---|
| Katalog-ID: |
ELV040961117 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV040961117 | ||
| 003 | DE-627 | ||
| 005 | 20230624081343.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180725s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.placenta.2017.09.011 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000095A.pica |
| 035 | |a (DE-627)ELV040961117 | ||
| 035 | |a (ELSEVIER)S0143-4004(17)31125-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.44 |2 bkl | ||
| 100 | 1 | |a David, Anna L. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth restriction |
| 264 | 1 | |c 2017 | |
| 300 | |a 7 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Intrauterine growth restriction (IUGR) is a serious pregnancy complication affecting approximately 8% of all pregnancies. The aetiology is believed to be insufficient maternal uteroplacental perfusion which prevents adequate nutrient and oxygen availability for the fetus. There is no treatment that can improve uteroplacental perfusion and thereby increase fetal growth in the uterus. | ||
| 650 | 7 | |a Intrauterine growth restriction |2 Elsevier | |
| 650 | 7 | |a Uterine blood flow |2 Elsevier | |
| 650 | 7 | |a Gene therapy |2 Elsevier | |
| 650 | 7 | |a Vascular endothelial growth factor |2 Elsevier | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Luukkonen, P. ELSEVIER |t O045 : Bioactive lipids in the human liver in ‘Common NAFLD’ and ‘PNPLA3 NAFLD’ |d 2015 |g Amsterdam [u.a.] |w (DE-627)ELV012874620 |
| 773 | 1 | 8 | |g volume:59 |g year:2017 |g pages:44-50 |g extent:7 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.placenta.2017.09.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.44 |j Parasitologie |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 59 |j 2017 |h 44-50 |g 7 |y 59.2017, S44-, (7 S.) | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
a l d al ald |
|---|---|
| matchkey_str |
davidannal:2017----:aenltrnatrvggnteayotetetfnru |
| hierarchy_sort_str |
2017 |
| bklnumber |
44.44 |
| publishDate |
2017 |
| allfields |
10.1016/j.placenta.2017.09.011 doi GBV00000000000095A.pica (DE-627)ELV040961117 (ELSEVIER)S0143-4004(17)31125-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl David, Anna L. verfasserin aut Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth restriction 2017 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Intrauterine growth restriction (IUGR) is a serious pregnancy complication affecting approximately 8% of all pregnancies. The aetiology is believed to be insufficient maternal uteroplacental perfusion which prevents adequate nutrient and oxygen availability for the fetus. There is no treatment that can improve uteroplacental perfusion and thereby increase fetal growth in the uterus. Intrauterine growth restriction Elsevier Uterine blood flow Elsevier Gene therapy Elsevier Vascular endothelial growth factor Elsevier Enthalten in Elsevier Luukkonen, P. ELSEVIER O045 : Bioactive lipids in the human liver in ‘Common NAFLD’ and ‘PNPLA3 NAFLD’ 2015 Amsterdam [u.a.] (DE-627)ELV012874620 volume:59 year:2017 pages:44-50 extent:7 https://doi.org/10.1016/j.placenta.2017.09.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 59 2017 44-50 7 59.2017, S44-, (7 S.) 045F 610 |
| spelling |
10.1016/j.placenta.2017.09.011 doi GBV00000000000095A.pica (DE-627)ELV040961117 (ELSEVIER)S0143-4004(17)31125-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl David, Anna L. verfasserin aut Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth restriction 2017 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Intrauterine growth restriction (IUGR) is a serious pregnancy complication affecting approximately 8% of all pregnancies. The aetiology is believed to be insufficient maternal uteroplacental perfusion which prevents adequate nutrient and oxygen availability for the fetus. There is no treatment that can improve uteroplacental perfusion and thereby increase fetal growth in the uterus. Intrauterine growth restriction Elsevier Uterine blood flow Elsevier Gene therapy Elsevier Vascular endothelial growth factor Elsevier Enthalten in Elsevier Luukkonen, P. ELSEVIER O045 : Bioactive lipids in the human liver in ‘Common NAFLD’ and ‘PNPLA3 NAFLD’ 2015 Amsterdam [u.a.] (DE-627)ELV012874620 volume:59 year:2017 pages:44-50 extent:7 https://doi.org/10.1016/j.placenta.2017.09.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 59 2017 44-50 7 59.2017, S44-, (7 S.) 045F 610 |
| allfields_unstemmed |
10.1016/j.placenta.2017.09.011 doi GBV00000000000095A.pica (DE-627)ELV040961117 (ELSEVIER)S0143-4004(17)31125-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl David, Anna L. verfasserin aut Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth restriction 2017 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Intrauterine growth restriction (IUGR) is a serious pregnancy complication affecting approximately 8% of all pregnancies. The aetiology is believed to be insufficient maternal uteroplacental perfusion which prevents adequate nutrient and oxygen availability for the fetus. There is no treatment that can improve uteroplacental perfusion and thereby increase fetal growth in the uterus. Intrauterine growth restriction Elsevier Uterine blood flow Elsevier Gene therapy Elsevier Vascular endothelial growth factor Elsevier Enthalten in Elsevier Luukkonen, P. ELSEVIER O045 : Bioactive lipids in the human liver in ‘Common NAFLD’ and ‘PNPLA3 NAFLD’ 2015 Amsterdam [u.a.] (DE-627)ELV012874620 volume:59 year:2017 pages:44-50 extent:7 https://doi.org/10.1016/j.placenta.2017.09.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 59 2017 44-50 7 59.2017, S44-, (7 S.) 045F 610 |
| allfieldsGer |
10.1016/j.placenta.2017.09.011 doi GBV00000000000095A.pica (DE-627)ELV040961117 (ELSEVIER)S0143-4004(17)31125-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl David, Anna L. verfasserin aut Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth restriction 2017 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Intrauterine growth restriction (IUGR) is a serious pregnancy complication affecting approximately 8% of all pregnancies. The aetiology is believed to be insufficient maternal uteroplacental perfusion which prevents adequate nutrient and oxygen availability for the fetus. There is no treatment that can improve uteroplacental perfusion and thereby increase fetal growth in the uterus. Intrauterine growth restriction Elsevier Uterine blood flow Elsevier Gene therapy Elsevier Vascular endothelial growth factor Elsevier Enthalten in Elsevier Luukkonen, P. ELSEVIER O045 : Bioactive lipids in the human liver in ‘Common NAFLD’ and ‘PNPLA3 NAFLD’ 2015 Amsterdam [u.a.] (DE-627)ELV012874620 volume:59 year:2017 pages:44-50 extent:7 https://doi.org/10.1016/j.placenta.2017.09.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 59 2017 44-50 7 59.2017, S44-, (7 S.) 045F 610 |
| allfieldsSound |
10.1016/j.placenta.2017.09.011 doi GBV00000000000095A.pica (DE-627)ELV040961117 (ELSEVIER)S0143-4004(17)31125-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl David, Anna L. verfasserin aut Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth restriction 2017 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Intrauterine growth restriction (IUGR) is a serious pregnancy complication affecting approximately 8% of all pregnancies. The aetiology is believed to be insufficient maternal uteroplacental perfusion which prevents adequate nutrient and oxygen availability for the fetus. There is no treatment that can improve uteroplacental perfusion and thereby increase fetal growth in the uterus. Intrauterine growth restriction Elsevier Uterine blood flow Elsevier Gene therapy Elsevier Vascular endothelial growth factor Elsevier Enthalten in Elsevier Luukkonen, P. ELSEVIER O045 : Bioactive lipids in the human liver in ‘Common NAFLD’ and ‘PNPLA3 NAFLD’ 2015 Amsterdam [u.a.] (DE-627)ELV012874620 volume:59 year:2017 pages:44-50 extent:7 https://doi.org/10.1016/j.placenta.2017.09.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 59 2017 44-50 7 59.2017, S44-, (7 S.) 045F 610 |
| language |
English |
| source |
Enthalten in O045 : Bioactive lipids in the human liver in ‘Common NAFLD’ and ‘PNPLA3 NAFLD’ Amsterdam [u.a.] volume:59 year:2017 pages:44-50 extent:7 |
| sourceStr |
Enthalten in O045 : Bioactive lipids in the human liver in ‘Common NAFLD’ and ‘PNPLA3 NAFLD’ Amsterdam [u.a.] volume:59 year:2017 pages:44-50 extent:7 |
| format_phy_str_mv |
Article |
| bklname |
Parasitologie |
| institution |
findex.gbv.de |
| topic_facet |
Intrauterine growth restriction Uterine blood flow Gene therapy Vascular endothelial growth factor |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
O045 : Bioactive lipids in the human liver in ‘Common NAFLD’ and ‘PNPLA3 NAFLD’ |
| authorswithroles_txt_mv |
David, Anna L. @@aut@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV012874620 |
| dewey-sort |
3610 |
| id |
ELV040961117 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV040961117</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624081343.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180725s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.placenta.2017.09.011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000095A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV040961117</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0143-4004(17)31125-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">David, Anna L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth restriction</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Intrauterine growth restriction (IUGR) is a serious pregnancy complication affecting approximately 8% of all pregnancies. The aetiology is believed to be insufficient maternal uteroplacental perfusion which prevents adequate nutrient and oxygen availability for the fetus. There is no treatment that can improve uteroplacental perfusion and thereby increase fetal growth in the uterus.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Intrauterine growth restriction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Uterine blood flow</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Gene therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Vascular endothelial growth factor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Luukkonen, P. ELSEVIER</subfield><subfield code="t">O045 : Bioactive lipids in the human liver in ‘Common NAFLD’ and ‘PNPLA3 NAFLD’</subfield><subfield code="d">2015</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV012874620</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:59</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:44-50</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.placenta.2017.09.011</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">59</subfield><subfield code="j">2017</subfield><subfield code="h">44-50</subfield><subfield code="g">7</subfield><subfield code="y">59.2017, S44-, (7 S.)</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
David, Anna L. |
| spellingShingle |
David, Anna L. ddc 610 bkl 44.44 Elsevier Intrauterine growth restriction Elsevier Uterine blood flow Elsevier Gene therapy Elsevier Vascular endothelial growth factor Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth restriction |
| authorStr |
David, Anna L. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV012874620 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.44 bkl Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth restriction Intrauterine growth restriction Elsevier Uterine blood flow Elsevier Gene therapy Elsevier Vascular endothelial growth factor Elsevier |
| topic |
ddc 610 bkl 44.44 Elsevier Intrauterine growth restriction Elsevier Uterine blood flow Elsevier Gene therapy Elsevier Vascular endothelial growth factor |
| topic_unstemmed |
ddc 610 bkl 44.44 Elsevier Intrauterine growth restriction Elsevier Uterine blood flow Elsevier Gene therapy Elsevier Vascular endothelial growth factor |
| topic_browse |
ddc 610 bkl 44.44 Elsevier Intrauterine growth restriction Elsevier Uterine blood flow Elsevier Gene therapy Elsevier Vascular endothelial growth factor |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| hierarchy_parent_title |
O045 : Bioactive lipids in the human liver in ‘Common NAFLD’ and ‘PNPLA3 NAFLD’ |
| hierarchy_parent_id |
ELV012874620 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
O045 : Bioactive lipids in the human liver in ‘Common NAFLD’ and ‘PNPLA3 NAFLD’ |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV012874620 |
| title |
Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth restriction |
| ctrlnum |
(DE-627)ELV040961117 (ELSEVIER)S0143-4004(17)31125-6 |
| title_full |
Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth restriction |
| author_sort |
David, Anna L. |
| journal |
O045 : Bioactive lipids in the human liver in ‘Common NAFLD’ and ‘PNPLA3 NAFLD’ |
| journalStr |
O045 : Bioactive lipids in the human liver in ‘Common NAFLD’ and ‘PNPLA3 NAFLD’ |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
44 |
| author_browse |
David, Anna L. |
| container_volume |
59 |
| physical |
7 |
| class |
610 610 DE-600 610 VZ 44.44 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
David, Anna L. |
| doi_str_mv |
10.1016/j.placenta.2017.09.011 |
| dewey-full |
610 |
| title_sort |
maternal uterine artery vegf gene therapy for treatment of intrauterine growth restriction |
| title_auth |
Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth restriction |
| abstract |
Intrauterine growth restriction (IUGR) is a serious pregnancy complication affecting approximately 8% of all pregnancies. The aetiology is believed to be insufficient maternal uteroplacental perfusion which prevents adequate nutrient and oxygen availability for the fetus. There is no treatment that can improve uteroplacental perfusion and thereby increase fetal growth in the uterus. |
| abstractGer |
Intrauterine growth restriction (IUGR) is a serious pregnancy complication affecting approximately 8% of all pregnancies. The aetiology is believed to be insufficient maternal uteroplacental perfusion which prevents adequate nutrient and oxygen availability for the fetus. There is no treatment that can improve uteroplacental perfusion and thereby increase fetal growth in the uterus. |
| abstract_unstemmed |
Intrauterine growth restriction (IUGR) is a serious pregnancy complication affecting approximately 8% of all pregnancies. The aetiology is believed to be insufficient maternal uteroplacental perfusion which prevents adequate nutrient and oxygen availability for the fetus. There is no treatment that can improve uteroplacental perfusion and thereby increase fetal growth in the uterus. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth restriction |
| url |
https://doi.org/10.1016/j.placenta.2017.09.011 |
| remote_bool |
true |
| ppnlink |
ELV012874620 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1016/j.placenta.2017.09.011 |
| up_date |
2024-07-06T18:51:09.467Z |
| _version_ |
1803856767318228992 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV040961117</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624081343.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180725s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.placenta.2017.09.011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000095A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV040961117</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0143-4004(17)31125-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">David, Anna L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth restriction</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Intrauterine growth restriction (IUGR) is a serious pregnancy complication affecting approximately 8% of all pregnancies. The aetiology is believed to be insufficient maternal uteroplacental perfusion which prevents adequate nutrient and oxygen availability for the fetus. There is no treatment that can improve uteroplacental perfusion and thereby increase fetal growth in the uterus.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Intrauterine growth restriction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Uterine blood flow</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Gene therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Vascular endothelial growth factor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Luukkonen, P. ELSEVIER</subfield><subfield code="t">O045 : Bioactive lipids in the human liver in ‘Common NAFLD’ and ‘PNPLA3 NAFLD’</subfield><subfield code="d">2015</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV012874620</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:59</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:44-50</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.placenta.2017.09.011</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">59</subfield><subfield code="j">2017</subfield><subfield code="h">44-50</subfield><subfield code="g">7</subfield><subfield code="y">59.2017, S44-, (7 S.)</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4004526 |